Published: Sun, April 22, 2018
Business | By Tara Barton

Last Week Gilead Sciences, Inc. (NASDAQ:GILD) Ratings


During the same period in the prior year, the firm earned $2.70 EPS. equities research analysts expect that Gilead Sciences will post 6.32 earnings per share for the current year. GILD's profit will be $2.07B for 11.59 P/E if the $1.59 EPS becomes a reality. After $1.60 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth. The firm owned 68,800 shares of the biopharmaceutical company's stock after acquiring an additional 19,833 shares during the quarter. Platinum Investment Management Ltd. now owns 3,044,930 shares of the biopharmaceutical company's stock valued at $218,138,000 after buying an additional 145,300 shares in the last quarter. Hologic, Inc. (NASDAQ:HOLX) has declined 11.91% since April 22, 2017 and is downtrending. It has underperformed by 11.55% the S&P500.

Cobblestone Capital Advisors Llc decreased Gilead Sciences Inc (GILD) stake by 9.54% reported in 2017Q4 SEC filing. Zeke Capital Advisors Llc sold 6,422 shares as Gilead Sciences Inc Com (GILD)'s stock rose 1.93%. Weiss Asset Management Lp who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $96.09 billion market cap company. The stock decreased 0.99% or $0.74 during the last trading session, reaching $73.7. The shares were sold at an average price of $77.92, for a total transaction of $4,675,200.00. First Merchants Corporation (NASDAQ:FRME) has risen 8.92% since April 22, 2017 and is uptrending. GILD underperformed by 1.76% the S&P500. About 2.90M shares traded or Infinity% up from the average. It also upped Danaher Corp Del (NYSE:DHR) stake by 3,795 shares and now owns 293,118 shares. American Electric Power (NYSE:AEP) was reduced too.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 75% are positive. On Friday, February 5 the stock rating was initiated by Leerink Swann with "Outperform". The firm earned "Outperform" rating on Wednesday, July 29 by Oppenheimer. On Thursday, December 21 the stock of Gilead Sciences, Inc. On Monday, February 12 the rating was maintained by Mizuho with "Buy".

GILD opened at $73.70 on Friday. The rating was maintained by Cowen & Co on Wednesday, February 7 with "Buy".

First Finance In invested 0.01% in Gilead Sciences, Inc. Jefferies maintained the shares of GILD in report on Tuesday, March 15 with "Hold" rating. The approval of Gilead's latest triple HIV therapy, Biktarvy, is likely to provide an impetus to the stock as Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy post Kite acquisition. (NASDAQ:GILD). Douglass Winthrop Advsrs Ltd Co owns 18,305 shares for 0.07% of their portfolio. The stock of NXP Semiconductors N.V. (NASDAQ:NXPI) has "Hold" rating given on Thursday, February 8 by Bernstein. The firm has "Overweight" rating given on Friday, April 8 by Pacific Crest.

Since January 2, 2018, it had 0 insider buys, and 18 sales for $39.95 million activity. Macquarie Group Ltd. raised its position in shares of Gilead Sciences by 26.6% in the third quarter. Meyers James R sold 100,000 shares worth $8.02M. Shares for $4.68M were sold by WILSON GAYLE E. Washington Robin L sold $401,566 worth of stock or 5,000 shares. Hanson & Doremus Investment Management boosted its position in shares of Gilead Sciences by 806.5% during the 3rd quarter.

Arsenal player ratings vs West Ham: Alexandre Lacazette to the rescue
There was a bigger turnout on Sunday, although there were still a few thousand empty seats at the Emirates. Record signing Pierre-Emerick Aubameyang started on the bench and Petr Cech missed out with a hip injury.

In related news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, April 2nd. Insiders have sold a total of 308,600 shares of company stock valued at $24,328,226 over the last 90 days.

On May, 1 Gilead Sciences, Inc. It is negative, as 95 investors sold GILD shares while 545 reduced holdings.

Big Money Sentiment decreased to 0.8 in 2017 Q4. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the consensus estimate of $1.67 by $0.11.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. (NASDAQ:GILD). Chilton Cap Lc holds 15,995 shares or 0.1% of its portfolio. Amp Investors Limited holds 0.27% in Gilead Sciences, Inc. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $89.54. Aperio Gp Limited Liability Corporation has invested 0% in The Wendy's Company (NASDAQ:WEN). California Public Employees Retirement reported 515,437 shares.

ILLEGAL ACTIVITY NOTICE: "Gilead Sciences (GILD) Stake Raised by Vident Investment Advisory LLC" was published by StockNewsTimes and is the property of of StockNewsTimes.

Analysts await NXP Semiconductors N.V. (NASDAQ:NXPI) to report earnings on May, 2. Gilead Sciences's quarterly revenue was down 18.7% compared to the same quarter past year. Cwm Llc reported 83,213 shares. Winfield Associates owns 305 shares. The hedge fund run by Irving Kahn held 691,667 shares of the health care company at the end of 2017Q4, valued at $29.57 billion, down from 731,816 at the end of the previous reported quarter. Rowland & Commerce Counsel Adv reported 0.15% of its portfolio in Gilead Sciences, Inc. BidaskClub lowered shares of Gilead Sciences from a "hold" rating to a "sell" rating in a research note on Tuesday, January 9th. Following the transaction, the director now owns 182,258 shares in the company, valued at approximately $14,201,543.36. ValuEngine upgraded Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 8th. Therefore 29% are positive. Spirit Of America Mgmt Corp has invested 0.04% of its portfolio in Gilead Sciences, Inc. JP Morgan reinitiated the shares of WB in report on Wednesday, August 31 with "Overweight" rating. On Wednesday, August 31 the stock rating was initiated by JP Morgan with "Overweight". Jefferies maintained Momo Inc. The rating was upgraded by Zacks on Tuesday, August 18 to "Sell". Jefferies maintained it with "Buy" rating and $45.0 target in Tuesday, January 23 report. Peel Hunt maintained it with "Buy" rating and GBX 127 target in Friday, August 5 report. The stock of Aimmune Therapeutics, Inc.

Like this: